A distinction in Prader–Willi-related obesity treatment is the possibility of therapy with recombinant human growth hormone, which results in improved metabolic parameters, reduced body fat mass, increased muscle strength, and improved respiratory capacity. Here, GH1 is linked to obesity due to melanocortin 4 receptor deficiency.